Bioventus Reschedules Reporting of First Quarter Fiscal Year 2023 Financial Results to After Market Close on May 16, 2023

DURHAM, N.C., May 15, 2023 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will now report financial results for the first quarter of fiscal year 2023 after the market closes on Tuesday, May 16, 2023. The Company’s management will host a conference call at 5:00 p.m. Eastern Time that same day to discuss the results and provide a business update.

At this time, the Company expects to report revenue for the quarter ended April 1, 2023, of approximately $119 million and Adjusted EBITDA of approximately $17 million. The Company expects to be in compliance with all of its financial covenants under its bank agreement as of the end of the quarter.

To participate in the conference call, dial 1-833-636-0497 (domestic) or +1-412-902-4241 (international) and refer to the Bioventus, Inc. Conference Call.

A live webcast of the call and accompanying materials will also be provided on the “Investor Relations” section of the Company’s website at https://ir.bioventus.com/. The webcast will be archived at the same site and available for replay until May 15, 2024.

About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative Therapies and Surgical Solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com and follow the Company on LinkedIn and Twitter. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.

Investor and Media Inquiries:
Dave Crawford
919-474-6787
[email protected]